Kevin Lee, Bicycle Therapeutics CEO
September 7, 2022 10:53 AM EDT
R&D

Shoot­ing for a heav­i­ly pre-treat­ed niche can­cer mar­ket, Bi­cy­cle re­veals a 'mixed' da­ta cut

Max Gelman

Senior Editor

Less than two months af­ter ex­pand­ing its im­muno-on­col­o­gy part­ner­ship with Roche’s Genen­tech, Bi­cy­cle Ther­a­peu­tics tout­ed some new in-house da­ta on its lead pro­gram. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times